News & Updates

Show Multimedia Only

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

26 Mar 2025

For patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), prophylactic administration of rectal diclofenac does not appear to significantly reduce the incidence of pancreatitis after the procedure when compared with rectal indomethacin, according to a study from China.

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

26 Mar 2025

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

26 Mar 2025

In the treatment of locally advanced esophageal squamous cell carcinoma (ESCC), neoadjuvant chemoimmunotherapy may prolong overall and disease-free survival compared with neoadjuvant chemoradiotherapy, according to a study from China.

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

26 Mar 2025

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025 by

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

Baricitinib tied to hair regrowth in adolescents with severe AA

26 Mar 2025

Repeated LSD treatment for ADHD symptoms only as good as placebo

25 Mar 2025

Repeated administration of low-dose lysergic acid diethylamide (LSD) in an outpatient setting is not necessarily better than placebo at reducing symptoms of attention-deficit/hyperactivity disorder (ADHD), according to the results of a phase IIA trial.

Repeated LSD treatment for ADHD symptoms only as good as placebo

25 Mar 2025

DOR/ISL noninferior to comparator ARTs in two phase III trials

25 Mar 2025 by

In adults with virologically suppressed HIV-1* infection, switching to a two-drug regimen of doravirine 100 mg and islatravir 0.25 mg (DOR/ISL) was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or other baseline antiretroviral therapy (bART) regimens in maintaining viral suppression at 48 weeks, according to two phase III trials presented at CROI 2025.

DOR/ISL noninferior to comparator ARTs in two phase III trials

25 Mar 2025

SZC lowers hyperkalemia risk in HF patients on spironolactone

24 Mar 2025 by

The use of sodium zirconium cyclosilicate (SZC) among patients with heart failure (HF) and reduced ejection fraction (HFrEF) and hyperkalemia has significantly improved the proportion of those with normokalemia while on optimal spironolactone dose, a study has shown.

SZC lowers hyperkalemia risk in HF patients on spironolactone

24 Mar 2025

Acoramidis lowers mortality, CV hospitalization in ATTR-CM

24 Mar 2025

Treatment with acoramidis results in a decrease in the composite of all-cause mortality or first cardiovascular-related hospitalization (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), reports a study.

Acoramidis lowers mortality, CV hospitalization in ATTR-CM

24 Mar 2025

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

24 Mar 2025

The investigational anti–IL-23 monoclonal antibody QX004N appears to be well tolerated and have superior efficacy vs placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I study from China.

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

24 Mar 2025

Prior intravitreal injection tied to complications following cataract surgery

23 Mar 2025

Complications following cataract surgery appear to be more frequent among patients with prior intravitreal injection (IVI) therapy than among those without, as shown in a retrospective study.

Prior intravitreal injection tied to complications following cataract surgery

23 Mar 2025

Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis

23 Mar 2025

When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.

Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis

23 Mar 2025

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

Diclofenac no better than indomethacin for preventing post-ECRP pancreatitis

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

Neoadjuvant chemoimmunotherapy beneficial in locally advanced ESCC

Baricitinib tied to hair regrowth in adolescents with severe AA

Baricitinib tied to hair regrowth in adolescents with severe AA

Repeated LSD treatment for ADHD symptoms only as good as placebo

Repeated LSD treatment for ADHD symptoms only as good as placebo

DOR/ISL noninferior to comparator ARTs in two phase III trials

DOR/ISL noninferior to comparator ARTs in two phase III trials

SZC lowers hyperkalemia risk in HF patients on spironolactone

SZC lowers hyperkalemia risk in HF patients on spironolactone

Acoramidis lowers mortality, CV hospitalization in ATTR-CM

Acoramidis lowers mortality, CV hospitalization in ATTR-CM

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

Anti–IL-23 monoclonal antibody promising in plaque psoriasis

Prior intravitreal injection tied to complications following cataract surgery

Prior intravitreal injection tied to complications following cataract surgery

Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis

Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis